What is SLDB's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.74B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SLDB?

P/E (TTM) is n/a and 52-week range is $3.79 to $11.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SLDB figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SLDB?

The company profile lists revenue (TTM) near $15M, net income (TTM) near $-8.70B, EPS (TTM) near $-1.91 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Solid Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Charlestown, Massachusetts, US, 98.5M shares outstanding, ISIN US83422E2046 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Solid Biosciences Inc

$SLDB

Health Care · Biotechnology

IR Run Scenarios

$6.87

+0.73%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. The company also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Employees

121

Website

www.solidbio.com/

IPO

2018-01-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)